LUMINARI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.278
EU - Europa 11.584
AS - Asia 9.579
SA - Sud America 1.710
AF - Africa 211
OC - Oceania 72
Continente sconosciuto - Info sul continente non disponibili 9
Totale 50.443
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.968
GB - Regno Unito 4.254
CN - Cina 3.163
SG - Singapore 2.538
IT - Italia 1.906
DE - Germania 1.735
HK - Hong Kong 1.606
BR - Brasile 1.368
SE - Svezia 1.058
VN - Vietnam 640
RU - Federazione Russa 557
UA - Ucraina 499
TR - Turchia 431
FI - Finlandia 342
FR - Francia 288
KR - Corea 265
BG - Bulgaria 224
ID - Indonesia 173
CA - Canada 162
IN - India 150
AR - Argentina 148
JP - Giappone 147
NL - Olanda 133
IE - Irlanda 98
ES - Italia 83
MX - Messico 81
PL - Polonia 67
AU - Australia 65
ZA - Sudafrica 65
EC - Ecuador 62
AT - Austria 60
BD - Bangladesh 59
IQ - Iraq 48
MA - Marocco 48
PK - Pakistan 44
CH - Svizzera 43
CO - Colombia 36
LT - Lituania 36
EG - Egitto 34
BE - Belgio 31
IR - Iran 30
PT - Portogallo 29
MY - Malesia 28
AE - Emirati Arabi Uniti 27
IL - Israele 26
RO - Romania 25
SA - Arabia Saudita 25
BZ - Belize 23
PY - Paraguay 23
TW - Taiwan 23
KE - Kenya 21
CL - Cile 20
CZ - Repubblica Ceca 20
TH - Thailandia 19
JO - Giordania 18
UZ - Uzbekistan 17
VE - Venezuela 17
PE - Perù 16
PH - Filippine 16
AZ - Azerbaigian 12
DZ - Algeria 12
NO - Norvegia 12
UY - Uruguay 12
AL - Albania 11
DK - Danimarca 11
LB - Libano 11
TN - Tunisia 11
NP - Nepal 10
KZ - Kazakistan 9
LV - Lettonia 9
PA - Panama 9
BH - Bahrain 8
HU - Ungheria 8
BO - Bolivia 7
CR - Costa Rica 7
DO - Repubblica Dominicana 7
GR - Grecia 7
SK - Slovacchia (Repubblica Slovacca) 7
LU - Lussemburgo 6
NZ - Nuova Zelanda 6
OM - Oman 6
AM - Armenia 5
GE - Georgia 5
HN - Honduras 5
HR - Croazia 5
KG - Kirghizistan 5
RS - Serbia 5
EU - Europa 4
SI - Slovenia 4
SV - El Salvador 4
BF - Burkina Faso 3
TT - Trinidad e Tobago 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
EE - Estonia 2
GP - Guadalupe 2
GT - Guatemala 2
Totale 50.401
Salva come PNG Salva come JPEG
Città #
Fairfield 3.227
Southend 3.014
Santa Clara 2.502
Ashburn 2.397
Woodbridge 1.845
Hong Kong 1.594
Singapore 1.585
Houston 1.438
Chandler 1.207
Seattle 1.176
Wilmington 1.110
Cambridge 1.062
Frankfurt am Main 1.018
Hefei 994
Jacksonville 918
Dearborn 809
Ann Arbor 771
London 643
Beijing 609
Nyköping 600
Chicago 590
Los Angeles 499
San Diego 310
New York 262
Modena 258
Ho Chi Minh City 244
Princeton 237
Sofia 223
Salt Lake City 211
Seoul 211
Izmir 205
Redwood City 193
Eugene 185
Shanghai 185
The Dalles 163
Buffalo 161
Milan 149
São Paulo 148
Dallas 145
Helsinki 135
Moscow 135
Jakarta 133
Manchester 125
Council Bluffs 119
Hanoi 116
Munich 104
Elk Grove Village 99
Rome 99
San Jose 90
Dublin 87
Tampa 87
Columbus 83
Phoenix 75
Tokyo 74
Bremen 72
Bologna 71
Dong Ket 62
Falls Church 59
Sterling 58
Guangzhou 54
Des Moines 53
Warsaw 53
Boardman 51
Brooklyn 50
Lancaster 48
Rio de Janeiro 44
Turin 44
San Francisco 43
Toronto 43
Atlanta 42
Philadelphia 42
Stockholm 42
Tappahannock 42
Denver 41
Montreal 40
Nuremberg 40
Norwalk 39
Kilburn 38
Miami 37
Dulles 36
Kent 36
Turku 36
Redondo Beach 34
Belo Horizonte 32
Chennai 32
Istanbul 31
Amsterdam 30
Palermo 30
Parma 29
Brussels 28
Changsha 27
Boston 26
Johannesburg 26
Genoa 25
Nanjing 25
Washington 25
Casablanca 24
Kunming 24
Paris 24
Belize City 23
Totale 36.470
Salva come PNG Salva come JPEG
Nome #
Survival of cancer patients in Italy [La sopravvivenza dei pazienti oncologici in Italia [La sopravvivenza dei pazienti oncologici in Italia] 813
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study 747
Veno-occlusive disease nurse management: Development of a dynamic monitoring tool by the GITMO nursing group 658
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 624
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 586
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 479
Il linfoma mantellare 460
T-cell lymphoma in South America and Europe. 460
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 450
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 432
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 408
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 401
Transformed follicular lymphoma 400
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 371
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 355
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 353
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 349
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 348
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 339
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 335
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 328
Prognosis of follicular lymphomas 327
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial 319
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 315
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 302
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 302
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 300
Pure red-cell aplasia and epoetin therapy 295
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 295
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 295
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 293
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 291
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 288
A Gene Expression–based Model to Predict Metabolic Response after Two Courses of ABVD in Hodgkin Lymphoma Patients 288
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 286
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study 283
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 278
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 272
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 271
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 267
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 267
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 266
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 265
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 263
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 263
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 260
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 260
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 257
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 256
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 255
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 253
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 252
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy 251
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials 248
Bendamustine salvage therapy for T cell neoplasms 247
ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial 246
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 246
Reply to H.J.A. Adams et al and E. Laffon et al 245
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 244
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 244
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi Study 243
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 241
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 239
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 239
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 238
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 238
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. 237
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 237
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 237
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 236
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 236
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. 235
I tumori in Italia. Rapporto 2011: La sopravvivenza dei pazienti oncologici in Italia 235
Reply to T.P. Vassilakopoulos et al 235
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 233
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 233
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) 233
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 231
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 230
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 230
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma 226
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 225
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 224
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 224
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. 224
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 224
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale 224
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 223
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 223
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients 222
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 222
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 221
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 219
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 219
Prognostic tools in follicular lymphomas 218
Novel prognostic tools that identify high-risk follicular lymphoma 218
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi 217
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: A subset analysis of NCIC CTG LY12 216
Advances in Treatment of Follicular Lymphoma 216
Totale 29.534
Salva come PNG Salva come JPEG
Categoria #
all - tutte 213.705
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 213.705
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.586 0 0 0 0 0 467 432 672 469 662 494 390
2021/20224.650 324 538 515 270 133 271 244 296 469 364 801 425
2022/20233.837 418 392 321 330 460 502 96 392 465 96 220 145
2023/20243.994 113 206 185 229 1.433 205 411 668 78 79 89 298
2024/20259.485 312 88 141 699 1.711 1.460 723 509 1.270 555 927 1.090
2025/202610.120 1.149 893 1.687 2.467 2.999 925 0 0 0 0 0 0
Totale 51.081